Comparative Pharmacology
Head-to-head clinical analysis: NEPTAZANE versus TRUSOPT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEPTAZANE versus TRUSOPT.
NEPTAZANE vs TRUSOPT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methazolamide is a carbonic anhydrase inhibitor. It decreases intraocular pressure by inhibiting carbonic anhydrase in the ciliary epithelium, reducing aqueous humor secretion. It also has weak diuretic effects due to renal carbonic anhydrase inhibition.
Carbonic anhydrase inhibitor; decreases aqueous humor secretion by inhibiting carbonic anhydrase in the ciliary processes of the eye.
50 mg orally twice daily, increasing to 50 mg three times daily if needed. Maximum dose: 200 mg daily.
One drop of 2% solution in affected eye(s) twice daily, approximately 12 hours apart.
None Documented
None Documented
Terminal elimination half-life: 8-12 hours. In renal impairment, half-life may extend to 20-30 hours, requiring dose adjustment.
Terminal elimination half-life of dorzolamide in whole blood is approximately 4 months due to tight binding to carbonic anhydrase in red blood cells; however, the drug's clinical effect on intraocular pressure has a half-life of about 24 hours.
Renal: 100% as unchanged drug via tubular secretion. No biliary or fecal elimination.
Renal excretion as unchanged drug: approximately 70% of a topically applied dose is excreted renally; the remainder is eliminated via biliary/fecal routes (30%). Following oral administration, renal excretion accounts for about 65-70%.
Category C
Category C
Carbonic Anhydrase Inhibitor
Carbonic Anhydrase Inhibitor